REAL-WORLD EFFICACY AND SAFETY OF TELAPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY

被引：1

作者：

Mauss, S. ^{[1
]}

Boeker, K. H. W. ^{[2
]}

Eisenbach, C. ^{[3
]}

Moeller, B. ^{[4
,5
]}

Moog, G. ^{[6
,7
]}

Lutz, T. ^{[8
]}

Naumann, U. ^{[9
]}

Christensen, S. ^{[10
]}

Jung, M. -C. ^{[11
]}

Teuber, G. ^{[12
]}

Doss, M. Frank ^{[13
]}

Schuchmann, M. ^{[14
]}

Schott, E. ^{[15
]}

Alshuth, U. ^{[16
]}

Hueppe, D. ^{[17
]}

机构：

[1] Ctr HIV & Hepatogastroenterol, Dusseldorf, Germany

[2] Ctr Hepatol, Hannover, Germany

[3] Heidelberg Univ, Dept Gastroenterol, Heidelberg, Germany

[4] Ctr Gastroenterol, Berlin, Germany

[5] Ctr Liver, Berlin, Germany

[6] Ctr Gastroenterol, Kassel, Germany

[7] Ctr Liver, Kassel, Germany

[8] Infektiologikum, Frankfurt, Germany

[9] Ctr Med, Berlin, Germany

[10] Ctr Interdisciplinary Med, Munster, Germany

[11] Ctr Liver, Munich, Germany

[12] Interdisziplinaeres Facharztzentrum Sachsenhausen, IFS, Frankfurt, Germany

[13] Ctr Gastroenterol, Marburg, Germany

[14] Johannes Gutenberg Univ Mainz, Dept Med Gastroenterol & Hepatol 1, D-55122 Mainz, Germany

[15] Campus Virchow Klinikum, Dept Gastroenterol, Charite, Berlin, Germany

[16] Roche Pharma AG, Virol, Grenzach Wyhlen, Germany

[17] Ctr Gastroenterol, Herne, Germany

来源：

JOURNAL OF HEPATOLOGY | 2013年 / 58卷

关键词：

D O I：

10.1016/S0168-8278(13)60873-9

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

871

引用

页码：S357 / S358

页数：2

共 50 条

[1] REAL-WORLD EFFICACY AND SAFETY OF BOCEPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY
Moog, G.
Schober, A.
Antoni, C.
Bruch, H. R.
Herrmann, A.
John, C.
Steffens, H.
Leuschner, M.
Spengler, U.
Moeller, B.
Isernhagen, K.
Hueppe, D.
Alshuth, U.
Mauss, S.
[J]. JOURNAL OF HEPATOLOGY, 2013, 58 : S359 - S360
[2] REAL-WORLD EFFICACY OF BOCEPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN IN TREATMENT-EXPERIENCED PATIENTS: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY
Spengler, U.
Schober, A.
John, C.
Bruch, H. R.
Heyne, R.
Antoni, C.
Herrmann, A.
Schott, E.
Steffens, H.
Hoerster, H. -G.
Hueppe, D.
Alshuth, U.
Mauss, S.
Buggisch, P.
[J]. JOURNAL OF HEPATOLOGY, 2013, 58 : S374 - S374
[3] Efficacy and safety of eRVR patients treated with telaprevir, peginterferon alfa-2A and ribavirin: SVR Data from the German non-interventional PAN Study
Christensen, Stefan
Boeker, Klaus H.
Eisenbach, Christoph
Schuchmann, Marcus
Lutz, Thomas
Heyne, Renate
Moog, Gero
Mauss, Stefan
Jung, Maria-Christina
Teuber, Gerlinde
Emke, Franz
Naumann, Uwe
Doss, Margareta Frank
von Lucadou, Armand
Alshuth, Ulrich
Hueppe, Dietrich
[J]. HEPATOLOGY, 2013, 58 : 1127A - 1127A
[4] Real-world efficacy and safety of 28 week-therapy containing boceprevir, peginterferon alfa-2a and ribavirin in treatment-naive patients: first SVR data of German non-interventional PAN Study
Buggisch, Peter
Schober, Andreas
Bruch, Harald-Robert
Antoni, Christoph
Loehr, Hanns-Friedrich F.
Herrmann, Andreas
Steffens, Hermann
Moog, Gero
Haessner, Joachim
Hoerster, Hans-Georg
John, Christine
Schlueter, Hans-Joachim
Link, Ralph
Heyne, Renate
Spengler, Ulrich
Alshuth, Ulrich
Boeker, Klaus H.
[J]. HEPATOLOGY, 2013, 58 : 1159A - 1159A
[5] Twice Daily Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV Genotype 1 Liver Transplant Recipients: Interim Safety/Efficacy of the REFRESH Study
Brown, R.
Russo, M.
Levitsky, J.
Brown, K.
Fontana, R.
Vargas, H.
Yoshida, E.
Bsharat, M.
Rubin, R.
[J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 145 - 145
[6] BASELINE CHARACTERISTICS AND TREATMENT EFFICACY OF TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA-2a AND RIBAVIRIN IN 253 HCV GENOTYPE 1 NONRESPONDER PATIENTS IN A REAL-WORLD SETTING
Hofmann, W. P.
Mauss, S.
Baumgarten, A.
Boeker, K. H. W.
Link, R.
Naumann, U.
Geyer, P. R.
Schuchmann, M.
Stoehr, A.
Loehr, H.
Schober, A.
Moog, G.
Holm, S.
Heyne, R.
Eisenbach, C.
Lutz, T.
Alshuth, U.
Hueppe, D.
[J]. JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S466 - S466
[7] TELAPREVIR COMBINATION WITH PEGINTERFERON ALFA-2A/RIBAVIRIN IN HCV/HIV COINFECTED PATIENTS: 24-WEEK TREATMENT INTERIM ANALYSIS
Sherman, Kenneth E.
Rockstroh, Juergen K.
Dieterich, Douglas T.
Soriano, Vincent
Girard, Pierre-Marie
McCallister, Scott
Adda, Nathalie
Adiwijaya, Bambang S.
Mahnke, Lisa
Sulkowski, Mark S.
[J]. HEPATOLOGY, 2011, 54 : 1431A - 1431A
[8] Interim analysis results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C
Jacobson, Ira M.
Everson, Gregory T.
Gordon, Stuart C.
Kauffman, Robert
McNair, Lindsay
Muir, Andrew
McHutchison, John G.
[J]. HEPATOLOGY, 2007, 46 (04) : 315A - 316A
[9] Interim analysis of the safety and efficacy of peginterferon alfa-2a plus ribavirin in chronic hepatitis C patients unable to tolerate or nonresponsive to treatment with peginterferon alfa-2b plus ribavirin
Rustgi, VK
Esposito, S
Freilich, B
Lopez-Talavera, JC
Lentz, E
Shiffman, ML
[J]. HEPATOLOGY, 2005, 42 (04) : 692A - 692A
[10] Twice Daily Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV Genotype 1 Liver Transplant Recipients: Interim Pharmacokinetics of the REFRESH Study.
Vargas, H.
Dai, Y.
Brown, K.
Russo, M.
Yoshida, E.
Fontana, R.
Levitsky, J.
Rubin, R.
Garg, V.
Brown, R.
[J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 347 - 347

← 1 2 3 4 5 →